Work

A Tale of Two Receptors: Insulin and Insulin-Like Growth Factor Signaling in Cancer

Year: 2014

Type: article

Abstract: Inhibition of the type I IGF receptor (IGF1R) has been the focus of numerous clinical trials. Two reports in this issue describe the results of phase I trials of an IGF1R tyrosine kinase inhibitor OSI-906. This commentary will describe the complex endocrine changes induced by these types of agents. Clin Cancer Res; 21(4); 667–9. ©2014 AACR. See related articles by Jones et al., p. 693, and Puzanov et al., p. 701

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-14-2056

Author: Douglas Yee

Institutions: University of Minnesota, Masonic Cancer Center

Language: English

Topic: Growth Hormone and Insulin-like Growth Factors

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute